These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 27754806

  • 21. The level of TSH appeared favourable in maintaining bone mineral density in postmenopausal women.
    Baqi L, Payer J, Killinger Z, Susienkova K, Jackuliak P, Cierny D, Langer P.
    Endocr Regul; 2010 Jan; 44(1):9-15. PubMed ID: 20151763
    [Abstract] [Full Text] [Related]

  • 22. Effect of hypoparathyroid on bone mineral density of lumber spine in postmenopausal women with differentiated thyroid cancinoma.
    Bai Y, Huo Y, Yu F, Wang D, Ma C.
    Hell J Nucl Med; 2017 Jan; 20 Suppl():7-13. PubMed ID: 29324909
    [Abstract] [Full Text] [Related]

  • 23. The effect of long-term thyroid-stimulating hormone suppressive therapy on the cognitive function of elderly patients with differentiated thyroid carcinoma.
    Moon JH, Ahn S, Seo J, Han JW, Kim KM, Choi SH, Lim S, Park YJ, Park DJ, Kim KW, Jang HC.
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3782-9. PubMed ID: 25029415
    [Abstract] [Full Text] [Related]

  • 24. The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma.
    Kim MK, Yun KJ, Kim MH, Lim DJ, Kwon HS, Song KH, Kang MI, Baek KH.
    Bone; 2015 Feb; 71():101-5. PubMed ID: 25445448
    [Abstract] [Full Text] [Related]

  • 25. Effect of TSH Suppression Therapy on Bone Mineral Density in Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis.
    Ku EJ, Yoo WS, Lee EK, Ahn HY, Woo SH, Hong JH, Chung HK, Park JW.
    J Clin Endocrinol Metab; 2021 Nov 19; 106(12):3655-3667. PubMed ID: 34302730
    [Abstract] [Full Text] [Related]

  • 26. Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women.
    Fujiyama K, Kiriyama T, Ito M, Kimura H, Ashizawa K, Tsuruta M, Nagayama Y, Villadolid MC, Yokoyama N, Nagataki S.
    Thyroid; 1995 Feb 19; 5(1):13-7. PubMed ID: 7787427
    [Abstract] [Full Text] [Related]

  • 27. Treatment of acromegaly increases BMD but reduces trabecular bone score: a longitudinal study.
    Godang K, Olarescu NC, Bollerslev J, Heck A.
    Eur J Endocrinol; 2016 Aug 19; 175(2):155-64. PubMed ID: 27220351
    [Abstract] [Full Text] [Related]

  • 28. Bone mineral density and bone microarchitecture after long-term suppressive levothyroxine treatment of differentiated thyroid carcinoma in young adult patients.
    Mendonça Monteiro de Barros G, Madeira M, Vieira Neto L, de Paula Paranhos Neto F, Carvalho Mendonça LM, Corrêa Barbosa Lima I, Corbo R, Fleiuss Farias ML.
    J Bone Miner Metab; 2016 Jul 19; 34(4):417-21. PubMed ID: 26056020
    [Abstract] [Full Text] [Related]

  • 29. Effects of thyrotropin suppression on lumbar bone mineral density in postmenopausal women with differentiated thyroid carcinoma.
    Zhang P, Xi H, Yan R.
    Onco Targets Ther; 2018 Jul 19; 11():6687-6692. PubMed ID: 30349302
    [Abstract] [Full Text] [Related]

  • 30. Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance.
    Müller CG, Bayley TA, Harrison JE, Tsang R.
    Thyroid; 1995 Apr 19; 5(2):81-7. PubMed ID: 7647577
    [Abstract] [Full Text] [Related]

  • 31. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
    Marcocci C, Golia F, Vignali E, Pinchera A.
    J Bone Miner Res; 1997 Jan 19; 12(1):72-7. PubMed ID: 9240728
    [Abstract] [Full Text] [Related]

  • 32. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
    Karner I, Hrgović Z, Sijanović S, Buković D, Klobucar A, Usadel KH, Fassbender WJ.
    Eur J Med Res; 2005 Nov 16; 10(11):480-8. PubMed ID: 16354602
    [Abstract] [Full Text] [Related]

  • 33. Bone-density testing interval and transition to osteoporosis in differentiated thyroid carcinoma patients on TSH suppression therapy.
    Park H, Park J, Yoo H, Kim S, Koh JH, Jee JH, Min YK, Chung JH, Kim TH, Kang M, Kim SW.
    Clin Endocrinol (Oxf); 2022 Jul 16; 97(1):130-136. PubMed ID: 35174522
    [Abstract] [Full Text] [Related]

  • 34. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass.
    Jódar E, Begoña López M, García L, Rigopoulou D, Martínez G, Hawkins F.
    Osteoporos Int; 1998 Jul 16; 8(4):311-6. PubMed ID: 10024900
    [Abstract] [Full Text] [Related]

  • 35. Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis.
    Hawkins F, Rigopoulou D, Papapietro K, Lopez MB.
    Calcif Tissue Int; 1994 Jan 16; 54(1):16-9. PubMed ID: 8118747
    [Abstract] [Full Text] [Related]

  • 36. Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study.
    Appetecchia M.
    Horm Res; 2005 Jan 16; 64(6):293-8. PubMed ID: 16269872
    [Abstract] [Full Text] [Related]

  • 37. Assessment for bone health in patients with differentiated thyroid carcinoma after postoperative thyroid-stimulating hormone suppression therapy: a new fracture risk assessment algorithm.
    Jia H, Qu W, Cai X, Li M, Qian Y, Jiang Z, Zhang Z.
    Front Endocrinol (Lausanne); 2023 Jan 16; 14():1286947. PubMed ID: 38075039
    [Abstract] [Full Text] [Related]

  • 38. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.
    Diamond T, Nery L, Hales I.
    J Clin Endocrinol Metab; 1991 Jun 16; 72(6):1184-8. PubMed ID: 2026740
    [Abstract] [Full Text] [Related]

  • 39. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
    Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Biondi B, Iorio S, Giustina A, Amato G, Carella C.
    J Bone Miner Res; 2005 Mar 16; 20(3):480-6. PubMed ID: 15746993
    [Abstract] [Full Text] [Related]

  • 40. Global skeletal uptake of technetium-99m methylene diphosphonate in female patients receiving suppressive doses of L-thyroxine for differentiated thyroid cancer.
    Frusciante V, Carnevale V, Scillitani A, Zingrillo M, Dicembrino F, Giannatempo GM, Ghiggi MR, Minisola S.
    Eur J Nucl Med; 1998 Feb 16; 25(2):139-43. PubMed ID: 9473261
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.